<DOC>
	<DOCNO>NCT00446992</DOCNO>
	<brief_summary>The purpose study describe metabolic change first 16 week anti-psychotic treatment previously drug-na√Øve patient psychosis . We hypothesize drug-naive patient , great insulin resistance prior treatment predicts disproportionately great increase insulin resistance olanzapine treatment .</brief_summary>
	<brief_title>Diabetes Neuropsychiatric Disorders</brief_title>
	<detailed_description>Antipsychotic medication associate increase risk diabetes . We focus description early metabolic adverse effect clinical biochemical feature might predict adverse effect .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Age 1864 Maximum cumulative ( lifetime ) antipsychotic exposure one week , antipsychotic use previous 30 day enrol study No history diabetes serious medical neurological condition associate glucose intolerance insulin resistance ( eg , Cushing disease ) , Not take medication associate insulin resistance ( eg , hydrochlorothiazide , furosemide , ethacrynic acid , metolazone , chlorthalidone ) , beta blocker , glucocorticoid , phenytoin , nicotinic acid , cyclosporine , pentamidine , narcotic ) No history cocaine use previous 30 day , No laboratory evidence diabetes baseline ( fast glucose &lt; 126 mg/dL 2hour glucose &lt; 200 mg/dL glucose tolerance test )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective</keyword>
	<keyword>psychosis</keyword>
	<keyword>olanzapine</keyword>
</DOC>